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The development of neuropathic pain in response to peripheral nerve lesion for a large
part depends on microglia located at the dorsal horn of the spinal cord. Thus the injured
nerve initiates a response of microglia, which represents the start of a cascade of events
that leads to neuropathic pain development. For long it remained obscure how a nerve
injury in the periphery would initiate a microglia response in the dorsal horn of the spinal
cord. Recently, two chemokines have been suggested as potential factors that mediate
the communication between injured neurons and microglia namely CCL2 and CCL21. This
assumption is based on the following findings. Both chemokines are not found in healthy
neurons, but are expressed in response to neuronal injury. In injured dorsal root ganglion
cells CCL2 and CCL21 are expressed in vesicles in the soma and transported through the
axons of the dorsal root into the dorsal horn of the spinal cord. Finally, microglia in vitro
are known to respond to CCL2 and CCL21. Whereas the microglial chemokine receptor
involved in CCL21-induced neuropathic pain is not yet defined the situation concerning
the receptors for CCL2 in microglia in vivo is even less clear. Recent results obtained
in transgenic animals clearly show that microglia in vivo do not express CCR2 but that
peripheral myeloid cells and neurons do. This suggests that CCL2 expressed by injured
dorsal root neurons does not act as neuron-microglia signal in contrast to CCL21. Instead,
CCL2 in the injured dorsal root ganglia (DRG) may act as autocrine or paracrine signal
and may stimulate first or second order neurons in the pain cascade and/or attract CCR2-
expressing peripheral monocytes/macrophages to the spinal cord.
Keywords: neuropathic pain, microglia reaction, chemokines, neuron-microglia signaling, DRG neurons, LDV
vesicles, regulated release pathway
THE IMPORTANCE OF PAIN
An important aspect for the survival of all organisms is the sensa-
tion of potential harmful (noxious) threats, which often are expe-
rienced as pain (nociception). Accordingly, it has been known for
a long time that, even humans with congenital insensitivity to
pain often die as children because they fail to notice injuries and
illnesses, which underlies the importance of proper nociception
(see for review: Indo, 2001; Cox et al., 2006; Costigan et al.,
2009). Nociceptive neurons, like all primary afferent neurons,
innervate organs and the periphery. Their cell bodies are located
in the dorsal root ganglia (DRG) meaning that these neurons
reside outside of the central nervous system. There are two main
types of nociceptive neurons, unmyelinated C fibers and thin
myelinated Aδ fibers, that both mainly express so called transient
receptor potential (TRP) channels in order to respond to intense
mechanical or thermal stimuli (see for review: Dhaka et al., 2006;
Szallasi et al., 2007). Nociceptive neurons project to the dorsal
horn of the spinal cord (mainly to Lamina I and II) where they
signal to second-order neurons that project to higher pain centers
in hypothalamus and cortex. The nociceptive signal in the dorsal
horn of the spinal cord is also transmitted to interneurons that
are important for the fast nociceptive withdrawal reflex. The
physiologic nociceptive signal occurs in response to acute stimuli
and continues only in its presence; meaning that physiologically
nociceptive pain is rather short lived.
INFLAMMATORY PAIN
When tissue damage is more severe and causing a subsequent
inflammatory reaction, nociception is prolonged and sensitized,
thus the pain sensing system of the injured body parts undergoes
profound changes in its responsiveness (Scholz and Woolf, 2007;
Latremoliere and Woolf, 2009; Ren and Dubner, 2010; Johnson
et al., 2013). As a result of this pain hypersensitivity the affected
body parts are protected from further physical contact, which is
to aid the healing process. This type of pain or hypersensitivity is
directly caused by local inflammation in the injured or infected
body parts and is therefore called inflammatory pain. In fact one
of the hallmarks of inflammation in general is pain.
There are several ways by which nociception is sensitized by
inflammation. Inflammatory mediators might directly affect TRP
channel activity. Several compounds of the “inflammatory soup”
such as bradykinins, prostaglandins, leukotriene B4 and many
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others are known to sensitize TRPV1 activity (Szallasi et al.,
2007). Furthermore, it is known that pro-inflammatory cytokines
including IL-1β or TNFα also directly affect the signaling and
excitability of sensory neurons (see for review: Uçeyler et al.,
2009). Moreover, it has been shown that these pro-inflammatory
cytokines induce the release of several neuropeptides, such as
substance P (SP) or calcitonine gene-related peptide (CGRP)
from C fibers, which in turn initiate a higher expression of pain
sensing receptors and increased excitability in sensory neurons;
a process called neurogenic inflammation (Uçeyler et al., 2009).
Thus, the impact of inflammatory factors on the pain sensing
system is manifold and yet by far not completely understood.
The fact that injection of almost all known pro-inflammatory
factors can cause temporary pain or pain hypersensitivity shows
the robustness of this tight connection between inflammation and
pain sensation. Being in aid of the healing process, inflammatory
pain persists until the end of the repair process, it disappears
when inflammation is over. Thus, although inflammatory pain
may last for several weeks, it is generally temporary and thus
reversible.
THE DARK SIDE OF NOCICEPTION: NEUROPATHIC PAIN
Physiological pain is generally connected to pathology and in aid
of the organism. However, sometimes pain itself becomes the
primary clinical problem, meaning that pathological pain neither
protects nor supports healing. Pathological pain occurs when
nociceptive thresholds are reduced such that normally innocuous
stimuli become painful (allodynia) or when pain is sensed even
in the absence of a given stimulus. These phenomena are called
neuropathic pain and are due to changes higher up in the pain
cascade (spinal cord or brain stem), which are summarized as
central sensitization (Latremoliere and Woolf, 2009). Central
sensitization is characterized by reduced inhibition and increased
neuronal excitability/synaptic efficacy of the neurons of the noci-
ceptive pathway, which as a result uncouples pain sensation from
noxious stimuli (Latremoliere and Woolf, 2009).
Neuropathic pain is a consequence of damage of peripheral
nerves possibly caused by mechanical trauma, metabolic disorders
(diabetes), neurotoxic chemicals, infections or tumors (Dworkin
et al., 2003). Neuropathic pain treatment has conventionally been
applied on the basis of the underlying disease, which means that
it was anticipated that treatment of the disease would resolve
the pain symptoms (Dworkin et al., 2007). However, since the
primary disease and the resulting peripheral nerve damage only
initiates the cascade that subsequently leads to development and
maintenance of neuropathic pain, such an etiological approach
does not capture the essential feature of neuropathic pain;
central sensitization. As a consequence potential treatments for
neuropathic pain should prevent, inhibit or reverse the various
mechanisms occurring in central sensitization (Latremoliere and
Woolf, 2009).
Nerve damage surely causes an inflammatory reaction at the
lesion site, which is why neuropathic pain shares many features
with inflammatory pain. However, in contrast to inflammatory
pain it is the nerve injury itself with its profound impact that
most likely initiates central sensitization. For example, comparing
the changes in gene expression in the DRG neurons in animals
after induction of inflammatory pain (complete freund’s adjuvant
(CFA) injection) or nerve injury (chronic constriction injury
(CCI) model) revealed by far more changes in mRNA expression
in the latter paradigm, where hundreds of genes (approximately
5% of all detected genes) were affected by the nerve injury (Costi-
gan et al., 2002; Rodriguez Parkitna et al., 2006). These changes
were probable due to the loss of trophic support from the target
organ and/or caused by the various signals that are released at the
site of injury. The most prominent changes in mRNA expression
were attributed to the following functional classes: transcription
and translation, cellular metabolism, cytoskeleton, neurotrans-
mission and inflammation (Costigan et al., 2002). Those changes
are most likely linked to survival and re-grow of the injured
neurons, but also affect their sensitivity and signaling capacities.
CENTRAL SENSITIZATION
The injured peripheral neurons with their cell bodies in the DRGs
are not the only neurons of the pain axis that respond to nerve
injury. Electrophysiological changes in second order neurons that
project from lamina I and II of the dorsal horn to the brain
are characteristic for central sensitization and thus important for
the development of neuropathic pain. There is evidence that the
down-regulation of the potassium-chloride transporter 2 (KCC2)
in lamina I neurons, in response to peripheral nerve injury is
leading to an alteration in the chloride equilibrium of those
cells. This altered chloride equilibrium attenuates GABAergic
inhibitory synaptic transmission, or may even switch GABAergic
signals from inhibitory to excitatory (Coull et al., 2005). In lamina
II, neurons cause peripheral nerve injury an increase in synaptic
drive to excitatory neurons, whereas the opposite is the case
for inhibitory neurons in lamina II (Biggs et al., 2010). Thus,
peripheral nerve injury leads to a substantial state of disinhi-
bition, due to loss of GABAergic inhibition and a reduction
in glycinergic inhibitory signaling, which, in combination with
a strengthened excitatory signaling is essential for neuropathic
pain (Latremoliere and Woolf, 2009). These changes in dorsal
horn neurons show that peripheral nerve damage is “recognized”
in more central brain parts. Indeed various mRNA expression
profiling experiments show that peripheral nerve injury not only
affects the cell bodies of the injured nerve in the DRG (Costigan
et al., 2002; Rodriguez Parkitna et al., 2006), but also leads to
profound changes in the mRNA expression in the ipsilateral
dorsal horn of the spinal cord (Griffin et al., 2007). Depending
on the used peripheral nerve damage model these changes varied
considerably, both qualitatively and quantitatively. After spared
nerve injury (SNI) 184 mRNA transcripts were found changed
in the spinal cord, 310 changes in the mRNA expression pattern
were found in response to CCI and after spinal nerve ligation
(SNL) 399 mRNA changes were observed (Griffin et al., 2007).
All models have their own specific characteristics, which are for
example reflected by the differences in the death rate of DRG
neurons (see for review: Costigan et al., 2009) and may explain
the differences in gene expression. However, all these different
types of injury lead to neuropathic pain in animal models indi-
cating that those 54 mRNAs that were shared by all three models
might be important for central sensitization and neuropathic pain
(Griffin et al., 2007). Interestingly, the largest functional group
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out of those 54 was associated with immune function (Griffin
et al., 2007).
It has been recognized in the last decade that multiple
immunological processes are participating in neuropathic pain
phenomena. Peripheral nerve injury leads to an inflammatory
reaction directly at the site of the injured nerve and of the
DRGs, where an early and prominent infiltration of peripheral
macrophages is found observed (see for review: Scholz and Woolf,
2007). Given the importance of central sensitization in neuro-
pathic pain, however, it is required to understand the changes in
the dorsal horn of the spinal cord. Here the situation with respect
to peripheral macrophages is less clear. It was reported that an
early and prominent infiltration by peripheral macrophages does
not occur in the spinal cord; moreover, a depletion of peripheral
macrophages did not affect the development of neuropathic pain
(Rutkowski et al., 2000; Mitchell et al., 2008, ref 100 from Ren
and Dubner). In agreement with these findings, it was shown
that the blood-spinal cord barrier of the spinal cord is not greatly
affected after spinal nerve injury (Abram et al., 2006; Lu et al.,
2009; Calvo et al., 2010). On the other hand Zhang and co-
workers described that, in response to peripheral nerve injury
macrophages invade the spinal cord, where they subsequently dif-
ferentiate into microglia-like cells (Zhang et al., 2007). Moreover,
it was shown in another study that spinal nerve injury led to
a rapid and transient opening of the blood-spinal cord barrier
(Beggs et al., 2010). Thus, whether or not peripheral myeloid cells
invade the spinal cord in response to peripheral nerve injury is an
unresolved issue at the moment. Irrespective of these conflicting
results it is widely believed that the first cellular reaction in
response to peripheral nerve injury is a rapid change in microglia
morphology and physiology (see for recent review: McMahon and
Malcangio, 2009).
MICROGLIA
Microglia are the primary immune cells of the CNS parenchyma
that are derived from mesoderm as they stem from very early
myeloid cells (microglia precursors) that in the mouse at around
embryonic day 8–9 invade the developing nervous tissue (see for
review: Prinz and Mildner, 2011). Due to their origin microglia
share many features with peripheral myeloid cells, but they also
show brain specific properties (Ransohoff and Cardona, 2010;
Prinz and Mildner, 2011). In the adult brain and spinal cord
microglia are more or less evenly distributed, and it is undisputed
that these cells are the first line of defence which are activated
upon any type of brain injury (Kreutzberg, 1996; Streit, 2002;
van Rossum and Hanisch, 2004; Hanisch and Kettenmann, 2007;
Biber et al., 2006). Microglia have small cell bodies, fine, long and
heavily branched (ramified) processes that claim a territory which
does not overlap with the territory of neighboring microglia. Life
cell imaging studies using two-photon microscopy have shown
that microglia rapidly move those processes in the non-challenged
brain thereby palpating their direct environment, making them
very active “surveillant” cells, rather than “resting” as long been
thought (Nimmerjahn et al., 2005; Ransohoff and Cardona,
2010). In line with this “surveillance” function it was observed
that microglia respond to cell damage rapidly within several min-
utes (Nimmerjahn et al., 2005) with changes in their morphology
that follow a stereotypic pattern (Kreutzberg, 1996; Streit, 2002).
Since these morphological changes are stereotypic and occur
irrespective of the type of insult, the term “activated microglia”
became misleading over the years, because it suggests a single
functional state of those cells, which is known now not to be true
(Hanisch and Kettenmann, 2007; Ransohoff and Cardona, 2010).
It is now clear that microglia respond with a variety of different
reactions by integrating multifarious inputs (Schwartz et al., 2006;
Biber et al., 2007; Hanisch and Kettenmann, 2007; Ransohoff and
Perry, 2009; Ransohoff and Cardona, 2010). It is therefore con-
cluded that general terms like “microglia activation” or “activated
microglia” are not sufficient to depict the function of microglia.
Instead the different functional states of microglia should be
described with respect to a given physiological or pathological
situation (McMahon and Malcangio, 2009; Biber et al., 2014).
MICROGLIA IN NEUROPATHIC PAIN
Approximately two decades ago it was recognized that dorsal horn
microglia respond to peripheral nerve injury with a morpho-
logical change and up-regulation of several microglial markers
(Eriksson et al., 1993). These findings, together with early obser-
vations that inflammatory mediators are involved in neuropathic
pain (Watkins et al., 1994, 1995; DeLeo et al., 1997) and the
discovery that the microglial reaction in the spinal cord and
the development of neuropathic pain timely coincide (Colburn
et al., 1997, 1999; Coyle, 1998) have raised the assumption that
microglia are involved in neuropathic pain development (Watkins
et al., 2001). It is clear today that inhibition of various microglia-
specific receptors or effector molecules prevents the development
of neuropathic pain (Jin et al., 2003; Schäfers et al., 2003; Tsuda
et al., 2003; Terayama et al., 2008; Clark et al., 2009, 2010). Taken
together, it is widely accepted that microglia function is crucial
for the initiation of neuropathic pain (see for review: Ji et al.,
2006; McMahon and Malcangio, 2009; Svensson and Brodin,
2010; Trang et al., 2012; Clark et al., 2013; Tsuda et al., 2013).
However, while much has been revealed about the function of
numerous microglia factors and receptors like P2X4, P2X7, TLR2,
CX3CR1, BDNF and CatS (see fore excellent and recent reviews:
Ji et al., 2006; McMahon and Malcangio, 2009; Svensson and
Brodin, 2010; Trang et al., 2012; Clark et al., 2013; Tsuda et al.,
2013) comparably little is yet know about the mechanisms that
initiate the microglia response after peripheral nerve injury. From
a therapeutically point of view, however, it would be of crucial
interest to identify the signals that turn on the microglia response
after peripheral nerve injury.
CHEMOKINES: EFFECTIVE SIGNALING MOLECULES IN THE
BRAIN
The CNS is spatially highly organized. In general neuron-neuron
communication in the CNS is based on the regulated release of
various signaling molecules, like neurotransmitters, neuropep-
tides, neurohormones and neurotrophins. With few exceptions,
the release of these signaling molecules occurs at specific sites,
for example synapses between neurons. This specific release
requires a targeted intracellular transport of signaling molecules
to these sites. Accordingly, neurons have various systems for the
sorting, transportation and release of their numerous signaling
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molecules. Neurotransmitters are generally found in small, so-
called synaptic vesicles, which undergo recycling and are loaded
with neurotransmitters at the synapses. All protein or peptide
signaling molecules are delivered to the membrane in either the
constitutive or the regulated release pathway. This protein cargo
is synthesized in the endoplasmatic reticulum (ER) and sorted in
the trans-golgi-network (TGN) of the neurons. The vesicles of the
regulated release pathway belong to the large dense core vesicles
(LDV), with which neurons are able to sort, transport and release
protein-signaling molecules like neurotrophins or neuropeptides
at distinct sub-cellular sites (see for review: van Vliet et al., 2003;
Salio et al., 2006; Gottmann et al., 2009; Zhang et al., 2010).
Synapses between neurons are no longer considered the only
communication points in the CNS since there is accumulating
evidence for extrasynaptic release of signaling molecules and
since there is considerable communication ongoing also between
neurons and surrounding glia cells (Biber et al., 2007; Araque
and Navarrete, 2010; Faissner et al., 2010; Giaume et al., 2010).
Thus the concept of intracellular communication in the CNS has
substantially broadened and therefore it is not surprising that
new families of molecules are discussed at the moment to be
messengers in the brain.
Chemokines are small proteins (10–20 kDa) and originally
known from the peripheral immune system, where they orches-
trate various aspects of immunity. Originally chemokines were
described as chemotaxis-inducing cytokines; however, today it
is clear that chemokines control numerous aspects of immune
function making them important signaling molecules in health
and disease (Borroni et al., 2010; Sharma, 2010). The first reports
on chemokine expression in the brain focused on glia cells and
their potential role in neuroimmunology (Biber et al., 2002).
Apart from their expression in glia cells, at least five different
chemokines (CCL2, CCL21, CXCL10, CXCL12 and CX3CL1)
have been described in neurons in the last few years, predom-
inately under conditions of neuronal stress or injury (de Haas
et al., 2007; Biber et al., 2008; Miller et al., 2008). Since these
chemokines have electrophysiological effects in neurons (Oh
et al., 2002; Callewaere et al., 2006; Guyon et al., 2009; Miller
et al., 2009) and control glia cell function in brain pathology
(Cardona et al., 2008; Ransohoff, 2009), an important function
of these neuronal chemokines in conveying signals from injured
neurons has been suggested (de Haas et al., 2007; Ransohoff,
2009). The role of chemokines as microglia instruction signals has
gained particular interest in the field of neuropathic pain, where
at least three different neuronal chemokines (CX3XL1, CCL2
and CCL21) are playing different roles. Since the contribution
of CX3CL1/CX3CR1 signaling in neuropathic pain is covered by
Clark and Malcangio in this special research topic in Frontiers in
Cellular Neuroscience (Clark and Malcangio, 2014), we here will
focus on CCL2 and CCL21.
NEURONAL CCL2 AND CCL21 AND THEIR POTENTIAL ROLE
IN NEUROPATHIC PAIN
The chemokines CCL2 and CCL21 have both been described to
be up-regulated in injured DRG neurons (Zhang et al., 2007; Jung
et al., 2009; Miller et al., 2009; Biber et al., 2011) and their role
as neuron-microglia signaling factors involved in development of
neuropathic pain has been proposed (Zhang et al., 2007; Jung
et al., 2009; Miller et al., 2009; Biber et al., 2011). Both CCL2
and CCL21 are induced in the cell bodies of DRG neurons that
are located outside of the spinal cord. There would be thus
two prerequisites for effective microglia activation by neuronal
chemokines in the spinal cord: first adequate transport of these
chemokines from the DRG into the spinal cord is required and
second spinal microglia should express of the corresponding
receptors for CCL2 and CCL21.
SORTING AND TRANSPORT OF NEURONAL CCL21 AND CCL2
The first evidence that CCL21 is specifically expressed in endan-
gered neurons and may act as a signal from damaged neurons to
microglia was published more than a decade ago (Biber et al.,
2001). In subsequent studies in mice with disturbed CCL21
signaling inhibited microglia responses at the projection site of
injured neurons were found and it was speculated that CCL21
is transported to axon endings (Rappert et al., 2004; de Jong
et al., 2005). Corroborating this assumption it was observed that
neuronal CCL21 is located in vesicles in neuronal cell bodies,
axons and pre-synaptic terminals (de Jong et al., 2005). Subse-
quently CCL21-containing vesicles were identified as LDVs and
their preferential transport towards the axon ends was shown (de
Jong et al., 2008). These data were recently confirmed in dorsal
root ganglion cells, in which CCL21 expression is induced by
mechanical injury with subsequent transport of CCL21 through
the dorsal root into the primary afferents in the spinal cord (Biber
et al., 2011).
Similarly there is solid evidence from various models of neu-
ropathic pain that CCL2 is strongly upregulated in DRG neurons
(Tanaka et al., 2004; White et al., 2005; Zhang and De Koninck,
2006; Yang et al., 2007; Jung et al., 2008, 2009; Bhangoo et al.,
2009; Jeon et al., 2009; Thacker et al., 2009; Van Steenwinckel
et al., 2011). There is however, conflicting evidence about the
transport of CCL2 from the DRG into the dorsal horn of the
spinal cord. Whereas immunohistochemical findings suggested
the transport of CCL2 from the DRG into the spinal cord (Zhang
and De Koninck, 2006; Thacker et al., 2009; Van Steenwinckel
et al., 2011), a report on CCL2-mRFP1 expressing transgenic mice
showed that CCL2 expression was restricted to the lesioned DRG
(Jung et al., 2009). Since different lesion models of the spinal nerve
were used in these studies the question whether or not CCL2 is
transported from the DRG to the spinal cord might depend on
the lesion model.
The transport of CCL2, however, would require that CCL2
(like CCL21) is sorted into vesicles that allow such transport.
Indeed, there also is evidence that CCL2 is expressed in neuronal
vesicles (Jung et al., 2009) and a recent report using electron
microscopy described CCL2 expression in small clear vesicles and
LDV (Van Steenwinckel et al., 2011) suggesting that like CCL21
also CCL2 is sorted into vesicles of the regulated release pathway
which would allow its directed transport and release. However,
the mechanism of how neuronal chemokines are being sorted into
LDV is a yet not explored question.
The classic cargo of LDV like neurohormones, neuropeptides
and neurotrophins are all synthesized in a pre-pro-form and
sorted in the TGN (see for review: van Vliet et al., 2003; Salio
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et al., 2006; Gottmann et al., 2009; Zhang et al., 2010). The
“pre” of the pre-pro-form indicates the N-terminal signal peptide
which is cleaved to allow the entry of the protein into the ER
(van Vliet et al., 2003). Such N-terminal signal was also described
for CCL21 and its deletion resulted in cytoplasmic expression of
the chemokine showing that the entry into the ER is essential
for the sorting of CCL21 (de Jong et al., 2008). Interestingly,
bioinformatically methods using the online software SignalP3.01
would propose such N-terminal signal also for CCL2, which
would be cleaved off between position 23 and 24. Whether or
not the deletion of this proposed N-terminal signal would also
result in cytoplasmic expression of CCL2 is currently not known.
However, the entry into the ER only is the first step of the sorting
procedure and also is required for cargo that is sorted into the
constitutive release pathway (see for review: van Vliet et al., 2003;
Salio et al., 2006; Gottmann et al., 2009; Zhang et al., 2010).
For the further sorting of cargo of the regulated release pathway
into LDVs various proteases are involved and there is convincing
evidence that the processing of the pro-form is required for the
differential sorting of the cargo. Accordingly, various molecular
sorting signals in the pro-form of LDV cargo have been identified
(see for review: van Vliet et al., 2003; Salio et al., 2006; Gottmann
et al., 2009; Zhang et al., 2010).
In contrast to classical LDV cargo, neuronal chemokines are
not synthesized in a pre-pro-form, but in a pre-form, meaning
that they only have the N-terminal signal peptide allowing them
to enter the ER. Therefore, it is currently not understood how
exactly CCL21 and potentially CCL2 in neurons are subjected to
specific sorting into LDVs. However, the fact that both CCL21
and most likely CCL2 are sorted into LDVs the possibility arises
the possibility that both chemokines are transported to different
locations in neurons.
Taken together, various lines of evidence show that nerve
injury causes the expression of the chemokines CCL2 and CCL21
in peripheral neurons. After injury, their rapid expression first is
detected in the cell bodies of the neurons lying peripherally in the
DRG, after which both chemokines are most likely transported
through the dorsal root into the primary afferents in the spinal
cord. Thus both chemokines fulfil the first requirement of being
a signal that conveys the message of nerve damage from the
periphery into the spinal cord.
It is interesting to note here that CCL21 has yet never been
detected in healthy neurons, glia cells or other non-neuronal
cells in the brain such as endothelial cells. Thus, CCL21 in the
CNS is exclusively expressed in injured neurons and thus is one
the few inflammatory mediators in the CNS with such exclusive
cell specificity indicating a special role of this chemokine for the
communication between injured neurons and their surroundings.
In contrast, next to its neuronal expression, CCL2 in the brain
has been additionally described in glia cells (astrocytes, microglia)
(Biber et al., 2002). Furthermore, in peripheral nerve injury and
development of neuropathic pain expression of CCL2 has been
described in other cells than the injured DRG neurons, indicating
that being a potential message to microglia most likely is not the
only function of CCL2 after peripheral nerve injury (see below).
1http://www.cbs.dtu.dk/services/SignalP/
CCR2: A CHEMOKINE RECEPTOR IN MICROGLIA?
Since microglia are of myeloid origin and share many prop-
erties with peripheral monocytes/macrophages it was expected
that microglia express the receptor for CCL2, formerly called
monocyte chemoattractant protein-1 (MCP-1). There are thus
various reports in which CCR2 expressing cells are suggested to
be microglia (Abbadie et al., 2003; Zhang et al., 2007; Fernández-
López et al., 2012) or described as microglia/macrophages (Yao
and Tsirka, 2012) or referred to as amoeboid microglia cells (Deng
et al., 2009). Often CCR2 is discussed to be an important receptor
for the recruitment of microglia to injured brain areas (El Khoury
et al., 2007; Zhang et al., 2007; Deng et al., 2009; Raber et al., 2013)
and in this respect CCR2 has been described as receptor in spinal
cord microglia that enables these cells to respond to peripheral
nerve injury (Abbadie et al., 2003; Zhang et al., 2007).
On the other hand there is convincing evidence that microglia
do not express CCR2. Various recent mRNA expression studies
in acutely isolated microglia from the adult mouse brain did
not detect CCR2 mRNA expression in these cells (Olah et al.,
2012; Beutner et al., 2013; Hickman et al., 2013; Butovsky et al.,
2014) nor was CCR2 mRNA expression earlier found in cultured
microglia (Zuurman et al., 2003). Two different studies using
transgenic mouse models in which CCR2-expressing cells were
fluorescently labelled failed to detect the corresponding fluores-
cent signal in microglia in the healthy brain and in various dis-
ease models such as experimental autoimmune encephalomyelitis
(EAE), LPS-injection and sciatic nerve demyelination (Jung et al.,
2009; Mizutani et al., 2012). Finally there are various bone-
marrow transplantation studies and experiments with parabiotic
mice that show CCR2 expression solely in peripheral mono-
cytes/macrophages that have invaded the diseased central nervous
system (Mildner et al., 2007; Schilling et al., 2009a,b; Prinz and
Mildner, 2011; Mizutani et al., 2012).
How is this controversy around CCR2 expression in microglia
explained? With respect to their origin it is clear now that
microglia are derived from primitive c-kit+ erythromyeloid yolk
sac precursor cells that appear as early as embryonic day 8 in
the mouse (Ginhoux et al., 2010; Kierdorf et al., 2013). Impor-
tantly, only these cells invade the developing nervous tissue and
mature into microglia. Microglia never exchange with cells that
stem from fetal liver- or bone-marrow haematopoiesis, making
microglia a myeloid cell population in the adult that is exclusively
derived from primitive haematopoiesis (Ginhoux et al., 2010;
Schulz et al., 2012; Kierdorf et al., 2013). Microglia therefore are
a specialized and local cell population, that most likely display
self-renewing capacities without exchange with peripheral cells
under physiological conditions (Ajami et al., 2007; Ginhoux et al.,
2013). Since CCR2+/Lys6C high inflammatory monocytes, the
cells that may enter the diseased brain, are derived from definitive
haematopoiesis they are of different origin as microglia, yet it is
extremely difficult to distinguish both populations in the diseased
brain (see for recent review: Ginhoux et al., 2013; Neumann
and Wekerle, 2013; Biber et al., 2014). Since it was shown that
peripheral nerve injury led to a rapid (within 24 h) and tran-
sient (up to 7 days) opening of the blood-spinal cord barrier
(Beggs et al., 2010) and that CCR2-postive peripheral cells enter
the spinal cord in response to peripheral nerve injury (Zhang
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et al., 2007), the controversy about CCR2 expression in spinal
cord microglia could potentially be due to CCR2+ inflammatory
monocytes that have entered the spinal cord where they have been
mistaken for endogenous microglia.
The lack of CCR2 in microglia would not support a role
for neuronal CCL2 as microglia signal, however, the impor-
tance of CCL2 and its receptor CCR2 for the development of
nerve-injury induced neuropathic pain is undisputed. There is
an overwhelming body of literature that interfering with the
CCL2-CCR2 system (antagonists, knockouts, inhibitor studies)
reduces or prevents the development of neuropathic pain (see
for recent reviews: Gao and Ji, 2010; Clark et al., 2013). It is
obvious that the role of CCL2-CCR2 in this pathological pain
state is mnifold and likely acts on various levels. Given the known
role of CCL2 as an attracting factor for peripheral myeloid cells
in the CNS it is most likely that CCL2 also in the spinal cord
is important for the infiltration with monocytes/macrophages
(Zhang et al., 2007). However, CCR2 is not only expressed in
peripheral myeloid cells but also in DRG neurons and potentially
in second order neurons in lamina II of the spinal cord (Gao et al.,
2009; Jung et al., 2009). In these neurons several pro-nociceptive
electrophysiological effects of CCL2 like enhancement of enhance
glutamate receptor function or reduction of GABAergic signaling
(Gosselin et al., 2005; Gao et al., 2009; Gao and Ji, 2010; Clark
et al., 2013). Thus CCL2 in the DRG may act as autocrine signal
(neuron-neuron signal) and paracrine in the spinal cord where
neuronally released CCL2 may stimulate second order neurons
in the pain cascade. The primary afferents of the DRG neurons
are, however not the only cellular source of CCL2, as also spinal
cord astrocytes express CCL2 under conditions of neuropathic
pain (Gao and Ji, 2010; Clark et al., 2013). Thus interfering with
CCL2 signaling may inhibit neuropathic pain development at
various levels. Since microglia responses and neuropathic pain
development are closely connected to each other, it may very well
be that an inhibition of the pain cascade (by CCL2 antagonists for
example) also inhibits the pain-related reaction of microglia. Such
findings, however, are no formal proof of a direct effect of CCL2
in microglia.
CCL21 RECEPTORS IN MICROGLIA
Using CCL21-deficient mice (plt mutation) an important role of
this neuronal chemokine in the development of neuropathic pain
was demonstrated. Without neuronal CCL21 expression, animals
did not develop signs of tactile allodynia in response to spinal
nerve injury (Biber et al., 2011). This lack of neuropathic pain was
due to a failure in microglia to up-regulate P2X4 expression after
spinal nerve injury (Biber et al., 2011). In cultured microglia P2X4
mRNA and protein was induced by CCL21 stimulation showing
that this chemokine is the responsible neuronal trigger for P2X4
up-regulation in microglia and the development of neuropathic
pain (Biber et al., 2011), raising the question which microglia
receptor is responsible here.
There are two known receptors for CCL21 in mice: CCR7
and CXCR3 (Biber et al., 2006). The main receptor for CCL21 is
CCR7, which is not found in microglia under basal conditions,
but it can be induced in vitro and in vivo (Biber et al., 2001,
2002; Rappert et al., 2002; Dijkstra et al., 2006). In contrast,
CXCR3 is constitutively expressed in cultured microglia and
in acutely isolated microglia (Biber et al., 2001, 2002; Rappert
et al., 2002; de Haas et al., 2008). Thus cultured non-challenged
microglia from CXCR3-deficient animals are not responsive to
CCL21 stimulation (Rappert et al., 2002) but gain reactivity to
CCL21 after immunological challenges (Dijkstra et al., 2006).
Furthermore, CXCR3-deficient animals display markedly reduced
microglia activation after neuronal injury in the entorhinal cortex
lesion model (Rappert et al., 2004), indicating a prominent role of
CXCR3 in microglia for the detection of neuronal damage in the
nervous system. In order to understand which CCL21 receptor is
involved in the development of neuropathic pain, CCR7-/- and
CXCR3-/- animals were subjected to peripheral nerve damage.
CCR7-deficient animals displayed a somewhat milder disease
course, especially during the first days after spinal nerve injury
(Biber et al., 2011). This delay in allodynia development might
point to an induction of CCR7 expression in activated dorsal
horn microglia, similar to what was found in a mouse model of
multiple sclerosis (Dijkstra et al., 2006). However, in agreement
with earlier studies we were not able to detect any CCR7 mRNA
in the control spinal cord, neither was CCR7 mRNA induced
by the nerve lesion. Given this lack of CCR7 in spinal cord
tissue, the slightly milder disease development after spinal nerve
injury in CCR7-deficient animals is most likely due to a yet not
understood effect in the periphery. Surprisingly, the development
of neuropathic pain was also not affected in CXCR3-deficient
animals (Biber et al., 2011). Thus neither the deficiency of CCR7
or CXCR3 had a profound impact on the development of neuro-
pathic pain, in contrast to the striking phenotype in the absence
of their ligand CCL21.
The fact that only CCL21, but not the specific CXCR3 lig-
and CXCL10 or the specific CCR7 ligand CCL19 were able to
induce P2X4 mRNA expression in cultured mouse microglia
might point to another CCL21 receptor in these cells. Indeed,
we have recently provided functional evidence for a third, yet not
identified, CCL21 receptor in mouse glia cells (van Weering et al.,
2010), indicating that the question of CCL21 receptors in glia
cells is more complex than originally anticipated. Taken together,
the responsible receptor for the CCL21-dependent development
of neuropathic pain after spinal nerve injury remains to be
established.
CONCLUSIONS
Despite the similar expression pattern in response to periph-
eral nerve injury there are clear differences in function of neu-
ronal CCL2 and CCL21 in the development of neuropathic
pain (Figure 1). CCL2 in the injured DRG may act as local
autocrine signal (neuron-neuron signal) and paracrine in the
spinal cord where neuronally released CCL2 may stimulate sec-
ond order neurons in the pain cascade and/or attract CCR2-
expressing peripheral monocytes/macrophages. Neuronal CCL21
contributes to neuron-microglia signaling and is the crucial
trigger to up-regulate P2X4 receptors in spinal cord microglia, a
vital step in the cascade that leads to neuropathic pain. Thus both
neuronal chemokines play important roles in neuropathic pain
development are potential drug targets to prevent the formation
of neuropathic pain in response to peripheral nerve injury.
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FIGURE 1 | The different roles of CCL2 and CCL21 in the development
of neuropathic pain. Both chemokines are induced in DRG neurons in
response to nerve injury. CCL2 in the injured DRG may act as local
autocrine signal (neuron-neuron signal) and potentially paracrine in the
spinal cord where neuronally released CCL2 may stimulate second order
neurons in the pain cascade and/or attract CCR2-expressing peripheral
monocytes/macrophages. Since there are conflicting data about the
transport of CCL2 from the DRG into the spinal cord, alternatively CCL2
from astrocytes might also activate these target cells. Neuronal CCL21 is
transported from the DRG into the spinal cord and contributes to
neuron-microglia signaling. CCL21 is the crucial trigger to up-regulate P2X4
receptors in spinal cord microglia which is a vital step in the cascade that
leads to neuropathic pain. Although the receptor for CCL21 in spinal cord
microglia is an unsolved issue, this chemokine most likely acts as
neuron-microglia signal only, since effects of CCL21 in other cells of the
spinal cord have yet not been described.
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